羟苯磺酸钙胶囊联合益脉康片治疗视网膜静脉阻塞
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Treatment of calcium dobesilate tablets capsules combined yimaikang for retinal vein occlusion
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察羟苯磺酸钙胶囊联合益脉康片对视网膜静脉阻塞(retinal vein occlusion,RVO)的临床疗效。

    方法:将120例167眼RVO患者随机分为两组,对照组60例82眼口服羟苯磺酸钙胶囊,治疗组60例85眼口服羟苯磺酸钙胶囊和益脉康片,观察3个疗程,对治疗前后的视力、疗效进行比较。

    结果:治疗组60例85眼中,显效15例23眼,有效42例57眼,无效3例5眼,总有效率为94.1%; 对照组60例82眼中,显效8例12眼,有效38例49眼,无效14例21眼,有效率为74.4%,两组组间不良反应发生率较低。

    结论:羟苯磺酸钙胶囊联合益脉康片安全有效,治疗RVO疗效显著。

    Abstract:

    AIM: To observe the clinical curative effect of calcium dobesilate capsule and yimaikang tablet for treating retinal vein occlusion(RVO).

    METHODS:A total of 120 patients(167 eyes)with RVO were divided into 2 groups at random. The control group of 60 cases(82 eyes)were given calcium dobesilate capsule, and the treatment group of 60 cases(85 eyes)received calcium dobesilate capsule and yimaikang tablet. Changes of visual acuity and clinical effects after 3 courses of treatment were compared and analyzed for all patients.

    RESULTS: Markedly effective 15 cases(23 eyes), effective 42 cases(57 eyes)and invalid 3 cases(5 eyes)in the 60 cases(85 eyes)of the treatment group, the total effective rate was 94.1%. Eighty-two eyes of 60 cases in the control group, markedly effective in 8 cases(12 eyes), effective 38 cases(49 eyes), ineffective 14 cases(21 eyes), The total effective rate was 74.4% in the control group. There were significant differences between the 2 groups of curative effect, and low incidence rate of adverse reaction.

    CONCLUSION: Calcium dobesilate capsules and yimaikang tablet is effective and safe in the treatment of RVO.

    参考文献
    相似文献
    引证文献
引用本文

郑惠娟.羟苯磺酸钙胶囊联合益脉康片治疗视网膜静脉阻塞.国际眼科杂志, 2015,15(2):346-348.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2014-07-15
  • 最后修改日期:2015-01-15
  • 录用日期:
  • 在线发布日期: 2015-01-30
  • 出版日期:
文章二维码